# EDGAR Filing Document

**Accession Number:** 0001828316
**File Stem:** 0001828316-26-000021
**Filing Date:** 2026-4
**Character Count:** 5285
**Document Hash:** 84fef4186cad3b1629435abe06c0da5e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001828316-26-000021.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0001828316-26-000021

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260416

**FILED AS OF DATE**: 20260416

**DATE AS OF CHANGE**: 20260416

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pharming Group N.V.
- **CENTRAL INDEX KEY:** 0001828316
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39822
- **FILM NUMBER:** 26865680

**BUSINESS ADDRESS:**
- **STREET 1:** DARWINWEG 24
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CR
- **BUSINESS PHONE:** 31 (0)71 5247 400

**MAIL ADDRESS:**
- **STREET 1:** DARWINWEG 24
- **CITY:** LEIDEN
- **STATE:** P7
- **ZIP:** 2333 CR

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pharming Group Group N.V.
- **DATE OF NAME CHANGE:** 20201014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of April 2026**

**Commission File Number: 001-39822**

**Pharming Group N.V.**

(Exact Name of Registrant as Specified in Its Charter)

**Darwinweg 24**

**2333 CR Leiden**

**The Netherlands**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated April 16, 2026.

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | Pharming Group announces the 2026 Annual<br>General Meeting of Shareholders  |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Pharming Group N.V. | Pharming Group N.V. | Pharming Group N.V. |
| By: | /s/ Fabrice Chouraqui | /s/ Fabrice Chouraqui |
|  | Name: | Fabrice Chouraqui |
|  | Title: | CEO |

---

Date: April 16. 2026

------

![logo_greyxoriginalx.jpg](logo_greyxoriginalx.jpg)

**Pharming Group announces the 2026 Annual<br>General Meeting of Shareholders** 

**Leiden, the Netherlands, April 16, 2026:** Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company's 2026 Annual General Meeting of Shareholders (the "AGM") will be held on Thursday May 28, 2026, at 14:00 CET. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company's website under Investors/Shareholder Meetings.

The agenda of the AGM includes the proposal to appoint KPMG N.V. as the Company's external auditor for the financial years 2026 through 2028 and the proposals to amend the Remuneration policy for the Board of Directors regarding the fees to be paid to the Non-Executive Directors.<br>

The agenda of the AGM also includes the renewal of the authorizations for the Board of Directors to issue shares (including rights to acquire shares), and to repurchase shares.<br>

The AGM will be held at the Corpus Congress Centre, Willem Einthovenstraat 1, 2342 BH in Oegstgeest, the Netherlands, and will be webcast live.

**About Pharming Group N.V.**

Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S.<br>

For more information, visit www.pharming.com and find us on LinkedIn.

**Inside Information**

*This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.* 

**For further public information, contact:**

**Investor Relations**

Michael Levitan, VP Investor Relations & Corporate Communications

T: +1 (908) 705 1696

E: investor@pharming.com

**<br>Media Relations**

Global: Saskia Mehring, Corporate Communications Manager

T: +31 6 28 32 60 41

E: media.relations@pharming.com

<br> U.S.: Ethan Metelenis (Precision AQ on behalf of Pharming)

T: +1 (917) 882-9038<br>

Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)

T: +31 6 53 81 64 27

<br>